Abstract
In this study, we investigated the role of microRNA-363(miR-363) in ovarian cancer (OC) progression. MiR-363expression was downregulated in OC patient tissues and four OC cell lines (SKOV3, A2780, OVCAR and HO-8910). Low miR-363 levels were associated with advanced stage, lymph node metastasis, and poor prognosis in OC. MiR-363 overexpression decreased growth, colony formation, migration and invasiveness of SKOV3 cells. In addition, miR-363 overexpression in SKOV3 cells also decreased xenograft tumor size and weight in nude mice. Bioinformatics and dual luciferase reporter assays revealed that miR-363 suppresses expression of NIN1/RPN12 binding protein 1 homolog (NOB1) by binding to the 3’-UTR of its transcript. NOB1 expression inversely correlated with miR-363 levels in OC tissues. Thus miR-363 appears to play a tumor suppressor role in OC by inhibiting NOB1.
Highlights
Ovarian cancer (OC) is the most common gynecological malignancy with poor overall survival [1]
MiR-363 expression is decreased in ovarian cancer (OC) tissues and cell lines
Low miR-363 levels correlate with poor prognosis of OC patients
Summary
Ovarian cancer (OC) is the most common gynecological malignancy with poor overall survival [1]. The 5-year survival rate is 35–38% despite significant improvements in therapeutic strategies for OC during the past decade [2, 3]. Elucidating novel mechanisms of OC initiation and progression are critical to developing new and improved diagnostics and therapeutics. The role of miRNAs in various biological processes such as cellular proliferation, apoptosis, invasion, metastasis, migration, and stemness has been well established [5, 6]. The role of many miRNAs in the initiation, growth and metastasis of OC has already been identified [9, 10]. These miRNAs are promising prognostic biomarkers and potential therapeutic targets for OC
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
